Company: VCYT
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0001384101-25-000051
Chunk: 17

Company: VERACYTE, INC.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 17
---
 filed a Restated Certificate to implement a declassification of the Board of Directors over a three-year period, and provide for the annual election of directors for one-year terms, commencing upon the expiration of the directors’ then-current terms. The declassification of our Board of Directors began with the directors nominated for election at the 2024 Annual Meeting, and beginning with our 2026 Annual Meeting, all directors will stand for election for one-year terms.

Board Leadership Structure and Role in Risk Oversight

Our Nominating and Corporate Governance Committee periodically considers the leadership structure of our Board of Directors and makes such recommendations to our Board of Directors as our Nominating and Corporate Governance Committee deems appropriate. Our Board of Directors believes it is important to have flexibility in selecting the Chair of the Board of Directors and our Board of Directors leadership structure. The Board of Directors believes that is currently in the best interests of Veracyte and its stockholders for Dr. Epstein, an independent director, to serve as our Chair. Dr. Epstein has served on our Board of Directors since January 2015 and has deep familiarity with our business and our industry, including in-depth knowledge of the issues, opportunities and challenges facing our company and its business and make him well qualified to serve as our Chair. The Board of Directors believes that this leadership structure provides our Board of Directors with significant strengths and an independent leadership perspective. In his capacity as Chair, Dr. Epstein also serves ex officio on all committees of the Board of Directors and chairs executive sessions of the independent directors. The Board of Directors retains the authority to modify this structure as it deems appropriate. In making Board of Directors leadership structure determinations, the Board of Directors considers many factors, including the specific needs of the business and what is in the best interests of our stockholders. Any changes to the leadership structure of our Board of Directors, if made, will be disclosed on the Investor Relations portion of our website, and in our proxy materials for the next Annual Meeting of Stockholders. Our Board of Directors, in its sole discretion, may seek input from our stockholders on the leadership structure of the Board of Directors.

Our Board of Directors is responsible for overseeing the overall risk management process at Veracyte. The responsibility for managing risk rests with executive management, while the committees of the Board of Directors and the Board of Directors as a whole participate in the oversight process. The risk oversight process of the Board of Directors builds upon management’s enterprise risk management assessment and mitigation processes, which include reviews of long-term strategic and